We are live on ! Find out more
PETX

Aratana Therapeutics, Inc.
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

92 hedge funds and large institutions have $429M invested in Aratana Therapeutics, Inc. in 2015 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 36 increasing their positions, 24 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

913% more call options, than puts

Call options by funds: $304K | Put options by funds: $30K

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

50% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 24

0% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 13

1% less funds holding

Funds holding: 9392 (-1)

5% less capital invested

Capital invested by funds: $452M → $429M (-$22.6M)

Holders
92
Holders Change
-1
Holders Change %
-1.08%
% of All Funds
2.48%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
13
Increased
36
Reduced
24
Closed
13
Calls
$304K
Puts
$30K
Net Calls
+$274K
Net Calls Change
-$52K
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
1
Franklin Resources
California
$57.5M +$5.4M +373,965 +11%
Jennison Associates
2
Jennison Associates
New York
$51.9M +$4.5M +311,738 +10%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$38.1M -$12.7M -882,465 -26%
MAM
4
MPM Asset Management
Massachusetts
$32M
BFA
5
BlackRock Fund Advisors
California
$18.7M -$105K -7,239 -0.6%
AllianceBernstein
6
AllianceBernstein
Tennessee
$18.1M +$1.4M +96,814 +9%
BC
7
Broadfin Capital
New York
$17.1M
CCI
8
Columbus Circle Investors
$17M -$267K -18,518 -2%
Adage Capital Partners
9
Adage Capital Partners
Massachusetts
$15.9M -$2.17M -150,000 -13%
State Street
10
State Street
Massachusetts
$15M -$366K -25,359 -2%
Massachusetts Financial Services
11
Massachusetts Financial Services
Massachusetts
$14.8M -$210K -14,562 -1%
Vanguard Group
12
Vanguard Group
Pennsylvania
$14.8M +$251K +17,380 +2%
AIC
13
AWM Investment Company
New York
$9.07M
O
14
OppenheimerFunds
New York
$8.06M -$46.7K -3,233 -0.6%
BIT
15
BlackRock Institutional Trust
California
$7.84M +$243K +16,818 +3%
SCM
16
Sio Capital Management
New York
$6.12M +$3.27M +226,188 +127%
William Blair & Company
17
William Blair & Company
Illinois
$5.1M +$1.24M +85,960 +34%
Northern Trust
18
Northern Trust
Illinois
$5.04M +$249K +17,221 +5%
VAM
19
Visium Asset Management
New York
$4.75M -$15.9K -1,100 -0.3%
Fidelity Investments
20
Fidelity Investments
Massachusetts
$4.54M +$4.33M +300,000 New
RSCM
21
Rock Springs Capital Management
Maryland
$4.54M +$4.33M +300,000 New
Lazard Asset Management
22
Lazard Asset Management
New York
$4.13M -$5.74M -397,247 -59%
Principal Financial Group
23
Principal Financial Group
Iowa
$3.91M +$341K +23,600 +10%
HHC
24
Hutchin Hill Capital
New York
$3.81M +$8.66K +600 +0.2%
EAM
25
Eagle Asset Management
Florida
$3.04M -$16.9K -1,171 -0.6%

PETX Hedge Fund Activity: Q2 2015 in Review

92 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q2 2015, worth a combined $429M — down 5% from $452M a quarter earlier.

Fund positioning in PETX was balanced in Q2 2015: 13 funds opened new positions, 13 closed out, 36 added to existing stakes and 24 trimmed.

The largest buyer was Franklin Resources, adding an estimated $5.4M. The largest seller was Wellington Management Group, cutting an estimated $12.7M.

  • 92 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q2 2015, down from 93 in Q1 2015.
  • Funds reported $429M of Aratana Therapeutics, Inc. stock for Q2 2015, down 5% quarter-over-quarter.
  • 13 funds opened new Aratana Therapeutics, Inc. positions in Q2 2015 and 13 closed out, a net change of 0 holders.
  • The largest Aratana Therapeutics, Inc. buyer in Q2 2015 was Franklin Resources, an estimated $5.4M added.
  • The largest Aratana Therapeutics, Inc. seller in Q2 2015 was Wellington Management Group, an estimated $12.7M sold.

Based on aggregated 13F filings for Q2 2015.